NCT06526377Phase 2Not yet recruiting

Vilamakitug in Spondyloarthritis Placebo-controlled Investigation for Efficacy

Study sponsor: XBiotech, Inc. · XBIT

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-09Estimated
Enrollment · participants150Estimated
Source updated2026-05-14Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Assessment of Spondyloarthritis International Society (ASAS) criteria will be used to determine proportion of subjects achieving 40% Improvement (ASAS40 response). After: Measure: Percentage of participants achieving ASAS40..

Planned enrollment increased by 90 participants

Before: 60 participants (planned). After: 150 participants (planned).

Primary completion date changed

Before: 28 Feb 2027. After: Sep 2028.

Check registry source

· 1 field changed

Primary completion date changed

Before: 28 Feb 2025. After: 28 Feb 2027.

Check registry source